Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Aerobic Exercise-induced Effect on Cardiorespiratory Fitness, Endothelial Function, and Brain-derived Neurotrophic Factor in Patients With Ischaemic Heart Disease (ENDO-R)

Ffect of Different Aerobic Exercise Protocols in Cardiac Rehabilitation on Cardiorespiratory Fitness, Endothelial Function, and Brain-derived Neurotrophic Factor in Patients With Ischaemic Heart Disease (ENDO-R)

Ischaemic heart disease (IHD) remains the leading cause of cardiovascular mortality worldwide. Low peak oxygen uptake (VO2 peak), endothelial dysfunction, and reduced levels of brain-derived neurotrophic factor (BDNF) are well-established independent prognostic markers in IHD. Cumulative evidence indicates that aerobic exercise-based cardiac rehabilitation (CR) is an effective non-pharmacological therapy to improve these markers.

Although high-intensity interval training (HIIT) has been shown to enhance VO2 peak and endothelial function to a greater extent than moderate-intensity continuous training (MICT), the influence of high-intensity bout duration on these exercise-induced adaptations remains unclear. Notably, a previous meta-analysis by our group demonstrated that only long-interval HIIT (L-HIIT; > 1 min) yielded superior improvements in endothelial function, whereas short-interval HIIT (S-HIIT; ≤ 1 min) showed no significant differences compared to MICT. To date, no clinical trial has directly compared L-HIIT, S-HIIT, and MICT. Furthermore, to the best of our knowledge, there is no evidence regarding the effect of high-intensity bout duration on VO2 peak and BDNF adaptations in patients with IHD. Therefore, the main objective of this project will be to compare the effect of the three aerobic exercise methods on CRF, endothelial function, and BDNF concentration in patients with IHD. Complementarily, the effect of aerobic exercise, depending on the exercise method, on different mortality predictors will be compared. For this purpose, a multicentre randomised study will be carried out (2 hospitals in Elche and one in Alicante). Assessors will be blinded to the patients allocation. Participants will be aware about their allocation in the experimental groups due to the nature of the study. A total of 111 men and women with IHD, diagnosed between three and 12 months before the start of the intervention, aged between 45 and 75 years, and without limitations for the practice of exercise training, will be recruited. All patients will train 3 days a week for 12 weeks. Participants will be assessed before the intervention (i.e., pre), at 6 weeks of training (i.e., mid) ,and after the intervention (i.e., post). Physiological and psychological variables will be registered in the assessment periods. Training intensity will be individually prescribed based on the cardiopulmonary exercise test (CPET). Intensity exercise will be adapted after the first part of the intervention. Analysis of covariance will be used to compare the values of the three groups after the intervention for the continuous variables, including the pre-intervention value as a covariate, while a logistic regression model will be used for the categorical variables.

Studienübersicht

Studientyp

Interventionell

Einschreibung (Geschätzt)

111

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

  • Name: Jose Manuel Sarabia, PhD
  • Telefonnummer: 965222568
  • E-Mail: jsarabia@umh.es

Studieren Sie die Kontaktsicherung

  • Name: Agustin Manresa Rocamora, PhD
  • Telefonnummer: 626542131
  • E-Mail: amanresa@umh.es

Studienorte

      • Alicante, Spanien, 03010
        • Rekrutierung
        • Instituto de Investigación Sanitaria y Biomédica de Alicante
        • Kontakt:
    • Alicante
      • Elche, Alicante, Spanien, 03202
        • Rekrutierung
        • Centro de Investigación del deporte
        • Kontakt:
          • José M Sarabia Marín, PhD
          • Telefonnummer: +34965222568
          • E-Mail: jsarabia@umh.es

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

45 Jahre bis 75 Jahre (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Men and women aged between 45 and 75 years.
  • Diagnosed with acute myocardial infarction, unstable or stable angina.
  • Treated with percutaneous coronary intervention, coronary artery bypass grafting, or conservative treatment.
  • Event or intervention within 3 to 12 months prior to participation in the study.
  • Fluency in speaking and reading Spanish.
  • Residing in Elche or surrounding areas and able to attend evaluations and the exercise programme (not planning to be absent for more than one week during the programme).
  • Functional Class I-II according to the New York Heart Association (NYHA) classification.
  • No physical limitations for exercise.
  • Stable optimal medical treatment.
  • Physically inactive, defined as 1) not meeting the World Health Organization recommendations for both aerobic and strength exercise, and 2) not participating in a structured exercise programme at least 3 days per week for more than 3 months. Both conditions must be met for inclusion. Note: Casual walking is not considered grounds for exclusion.

Exclusion Criteria:

  • Use of walking assistive devices.
  • Treatment with chemotherapy for any type of cancer in the past 2 years.
  • Hospitalisation in an intensive care unit in the past 6 months for reasons other than the ischaemic event.
  • Acute myocardial infarction group IV Killip-Kimball.
  • Obesity grade III (≥40.0 kg/m²).
  • Medical contraindication for inclusion in an exercise programme.
  • Diabetes with uncontrolled blood glucose levels.
  • Poorly controlled hypertension: resting blood pressure > 180/110 mmHg.
  • Chest pain with exertion or ST-segment changes suggestive of residual ischemia during ergometry. Residual ischemia.
  • Severely reduced functional capacity on initial ergometry (<5 metabolic equivalent of task).
  • Left ventricular ejection fraction less than 50%.
  • Severe stenosis of the left main coronary artery (>50% significant disease).
  • Severe aortic stenosis, left ventricular outflow tract obstruction (e.g., obstructive hypertrophic cardiomyopathy) or aortic dissection.
  • Severe valvulopathy.
  • Acute pulmonary embolism or deep vein thrombosis.
  • Severe pulmonary hypertension.
  • Acute heart failure.
  • Acute endocarditis, myocarditis, or pericarditis.
  • Acute or chronic renal insufficiency (estimated glomerular filtration rate <30 ml/min).
  • Pulmonary fibrosis or interstitial disease (severe respiratory insufficiency or confirmed chronic obstructive pulmonary disease).
  • Uncontrolled cardiac arrhythmias/hemodynamically unstable.
  • Permanent or persistent/paroxysmal atrial fibrillation with episodes in the past 6 months.
  • High-grade cardiac block.
  • Presence of implantable devices: cardiac resynchronization therapy pacemaker, implantable cardioverter defibrillators, or pacemaker.
  • Presence of ischaemic symptoms during the incremental exercise test performed before the intervention.
  • Severe autonomic or peripheral neuropathy.
  • Use of nitrates in pharmacological treatment.
  • Any planned surgical or medical intervention during the study period.
  • Plans to participate in or current participation in other studies that may interfere with this study.
  • Current pregnancy or intention to become pregnant during the study period.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Single

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Moderate-intensity continuous training (MICT) group

Continuous exercise training on a cycle ergometer

Patients allocated to the MICT group will train on a cycle ergometer three days a week for 12 weeks (36 sessions). They will cycle continuously between the first and second ventilatory thresholds. The duration of each exercise session will be set according to the estimated energy expenditure of the long HIIT and short HIIT groups for each training block (energy expenditure-adjusted exercise sessions). All sessions will be supervised, and patients will be asked to avoid additional exercise. They will be allowed to perform extra physical activity (e.g., light walking) according to medical recommendations.

Experimental: Short high-intensity interval training (HIIT) group

High-intensity interval exercise performed on a cycle ergometer

Patients allocated to the Short HIIT group will train on a cycle ergometer three days a week for 12 weeks (36 sessions). They will perform from two to four 4-repetition sets of 1-min above the second ventilatory threshold. Patients will perform 1- and 3-min active recovery periods below the first ventilatory threshold between repetitions and sets, respectively. The total time spent at high intensity will range from eight to 16 min. All sessions will be supervised, and patients will be asked to avoid additional exercise training. They will be allowed to perform extra physical activity (e.g., light walking) according to medical recommendations.

Experimental: Long high-intensity interval training (HIIT) group

High-intensity interval exercise performed on a cycle ergometer

Patients allocated to the Long HIIT will train on a cycle ergometer three days a week for 12 weeks (36 sessions). They will perform from two to four 4-min high-intensity exercise bouts above the second ventilatory threshold separated by 4-min active recovery periods below the first ventilatory threshold. The total time spent at high intensity will range from eight to 16 min. All sessions will be supervised, and patients will be asked to avoid additional exercise training. They will be allowed to perform extra physical activity (e.g., light walking) according to medical recommendations.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change from baseline in endothelial function at 8 weeks
Zeitfenster: 8 weeks

Endothelial function (i.e., endothelial-dependent dilation) will be assessed by brachial FMD.

8 weeks
Change from baseline in endothelial function at 15 weeks
Zeitfenster: 15 weeks

Endothelial function (i.e., endothelial-dependent dilation) will be assessed by brachial FMD.

15 weeks
Change from baseline in VO2 peak at 8 weeks
Zeitfenster: 8 weeks

Participants will perform a symptom-limited CPET on a cycle ergometer.

8 weeks
Change from baseline in VO2 peak at 15 weeks
Zeitfenster: 15 weeks

Participants will perform a symptom-limited CPET on a cycle ergometer.

15 weeks
Change from baseline in resting serum BDNF concentration at 8 weeks
Zeitfenster: 8 weeks

Blood samples will be obtained through an indwelling catheter placed in the antecubital vein before the CPET.

8 weeks
Change from baseline in resting serum BDNF concentration at 15 weeks
Zeitfenster: 15 weeks

Blood samples will be obtained through an indwelling catheter placed in the antecubital vein before the CPET.

15 weeks
Change from baseline in exercise-induced effect on serum BDNF at 8 weeks
Zeitfenster: 8 weeks

Blood samples will be obtained through an indwelling catheter placed in the antecubital vein before and after the CPET.

8 weeks
Change from baseline in exercise-induced effect on serum BDNF at 15 weeks
Zeitfenster: 15 weeks

Blood samples will be obtained through an indwelling catheter placed in the antecubital vein before and after the CPET.

15 weeks

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change from baseline in endothelial-independent dilation at 8 and 15 weeks
Zeitfenster: 8 and 15 weeks

Brachial NMD will be used to measure endothelial-independent dilation.

8 and 15 weeks
Change from baseline in pulmonary function at 8 and 15 weeks
Zeitfenster: 8 and 15 weeks

Pulmonary function will be measured by spirometry

8 and 15 weeks
Change from baseline in resting cardiopulmonary parameters at 8 and 15 weeks
Zeitfenster: 8 and 15 weeks

Patients will be asked to rest for 5 min before stating the CPET.

8 and 15 weeks
Change from baseline in cardiopulmonary parameters at first and second ventilatory thresholds at 8 and 15 weeks
Zeitfenster: 8 and 15 weeks

First and second ventilatory threshold during the CPET will be analysed blindly using the ventilatory equivalents method.

8 and 15 weeks
Change from baseline in peak cardiopulmonary parameters at 8 and 15 weeks
Zeitfenster: 8 and 15 weeks
8 and 15 weeks
Change from baseline in cardiopulmonary variables measured during the recovery at 8 and 15 weeks
Zeitfenster: 8 and 15 weeks

Cardiopulmonary variables will be measured during the 3-min recovery period of the CPET.

8 and 15 weeks
Change from baseline in ventilatory efficiency at 8 and 15 weeks
Zeitfenster: 8 and 15 weeks

Ventilatory-related variables will be measured during the CPET.

8 and 15 weeks
Change from baseline in MacNew domains at 8 and 15 weeks
Zeitfenster: 8 and 15 weeks

The MacNew heart disease health-related quality of life instrument will be used as a disease-specific quality of life questionnaire. The MacNew consists of 27 items that fall into three domains (a 13-item physical limitations domain scale, a 14-item emotional function domain scale, and a 13-item social function domain scale). Scoring of the MacNew is straightforward. The maximum possible score in any domain is 7 (high quality of life) and the minimum is 1 (poor quality of life).

8 and 15 weeks
Change from baseline in body composition at 8 and 15 weeks
Zeitfenster: 8 and 15 weeks

Bioimpedance assessment will be conducted in fasting state.

8 and 15 weeks
Change from baseline in resting heart rate variability (HRV) at 8 and 15 weeks
Zeitfenster: 8 and 15 weeks

HRV will be measured after an overnight fasting period at the same time of day

8 and 15 weeks
Change from baseline in echocardiographic variables at 8 and 15 weeks
Zeitfenster: 8 and 15 weeks

A resting echocardiographic assessment will be performed before starting the CPET. The echocardiographic variables measured will be left ventricular end-diastolic diameter, septal and posterior wall thickness, left atrium dimension and volume, left ventricular ejection fraction (four-chamber and biplane Simpson's method, tricuspid annular plane systolic excursion, S' wave velocity, peak E and A wave velocities (in sinus rhythm), lateral and medial e' velocities, peak tricuspid regurgitation gradient, and velocity and gradient across the aortic valve.

8 and 15 weeks
Change from baseline in blood analysis variables at 15 weeks.
Zeitfenster: 15 weeks

Blood samples will be obtained after at least a 10-hours period of fasting.

15 weeks
Change from baseline in ability to inhibit cognitive interference at 8 and 15 weeks
Zeitfenster: 8 and 15 weeks

The Stroop test will be used to assess the ability to inhibit cognitive interference.

8 and 15 weeks
Change from baseline in verbal memory performance at 15 weeks
Zeitfenster: 15 weeks

Verbal learning and memory are assessed using the Rey Auditory Verbal Learning Test (RAVLT) under standardized environmental conditions. The procedure begins with five consecutive learning trials of a 15-word list (List A). The primary measures focus on the recall performance of this list at three key points during the test:

Immediate post-interference recall (A6): After presenting a new distractor list (List B), participants are asked to recall the original List A to assess resistance to interference.

20-minute delayed recall (A7): Assesses short-term retention. During this interval, participants complete the Corsi Block-Tapping Test (a visuospatial task) to prevent mental rehearsal of the words.

24-hour delayed recall (A8): Measures long-term memory consolidation via an unexpected telephone call where participants are asked to recall List A once again.

15 weeks
Change from baseline in visuospatial working memory performance at 15 weeks
Zeitfenster: 15 weeks

Visuospatial working memory is assessed using the Corsi Block-Tapping Test. Participants reproduce sequences of tapped blocks in both forward (same order) and backward (reverse order) conditions. Sequence lengths increase progressively until the participant fails two sequences of the same length. The reported outcome includes the Corsi span (defined as the maximum sequence length correctly reproduced) and the total number of correctly reproduced sequences. For both metrics, higher scores indicate better visuospatial working memory performance. This task is administered during the 20-minute interval of the RAVLT to prevent mental rehearsal of verbal material.

15 weeks

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

1. November 2024

Primärer Abschluss (Geschätzt)

1. Mai 2028

Studienabschluss (Geschätzt)

1. November 2028

Studienanmeldedaten

Zuerst eingereicht

15. Januar 2025

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

22. Januar 2025

Zuerst gepostet (Tatsächlich)

23. Januar 2025

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

13. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

9. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

JA

Beschreibung des IPD-Plans

The Instituto de Investigacion Sanitaria y Biomedica de Alicante (ISABIAL) Community in ZENODO. Depositing in ZENODO allows selecting the type of access for each file (open, embargoed; restricted; closed) and the license for use (Creative Commons Attribution 4.0 International, which requires citing the database and the original study, as well as mentioning any changes made; this is suggested at the institutional level for files identified with open access). It is important to note that the use of ZENODO is temporary, until it is viable to use the REPISALUD repository, from the Carlos III Health Institute, by the ISABIAL research community. At least two different files will be included: i) The one corresponding to the data set; ii) One or more files with complementary information about the characteristics of the variables and/or study metadata (project, authors, related publication, keywords, etc.).

IPD-Sharing-Zeitrahmen

From November 2027 to November 2030

Art der unterstützenden IPD-Freigabeinformationen

  • STUDIENPROTOKOLL
  • SAFT
  • ICF

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren